Duke-UNC Chapel Hill Immunotherapy Training Grant

摘要： 这是来自北卡罗来纳州查佩尔山大学（UNC-CH）和杜克大学的联合培训补助金 大学（杜克大学免疫治疗培训补助金; DUNC-IMTG）。DUNC-IMTG将培养博士后 专注于肿瘤免疫治疗和/或干细胞移植的转化和临床研究的研究员 免疫学这是一个快速增长和感兴趣的领域， 治疗患有多种不同形式癌症的患者。尽管有这种强烈的热情，这些地区是 在目前的培训计划中，由于缺乏训练有素的调查人员， 这些快速扩张的地区。 该方案每年支助在联合国大学-儿童和保健中心和杜克大学培训6名受训人员。我们有 在UNC-CH和杜克大学确定了21名具有出色资质的高级导师和3名初级导师 大学将指导受此培训计划支持的个人。这些研究人员的兴趣包括 疫苗设计和载体生成，过继细胞治疗，了解功能的新方法 检查点抑制剂，免疫细胞在肿瘤微环境中的作用，以及增强我们的 了解干细胞移植中免疫细胞的生物学。我们有一个非常新颖的 培训机制，重点是统计设计、生物信息学和 蛋白质组学和研讨会课程。重要的是，所有受训人员都参加这些课程， 两所院校的世界级导师。所有学员将参加 免疫治疗工作组，这是翻译团队，协助开发新的 免疫疗法，使所有学员参与生物标志物的开发和临床试验， 癌症患者的治疗。此外，我们有一个强大而全面的培训方法， 代表性不足的少数民族。 该计划的优势包括一个非常强大的导师组，具有丰富的经验培训 博士后研究员，一个杰出的领导小组，具有悠久的历史，培训翻译和临床 世界一流的疫苗和移植基础设施的存在， 和实施转化尖端临床试验，以及良好的合作培训记录 杜克大学和北卡罗来纳州大学之间的杰出培训成功的赠款， 查佩尔山。最后，我们确定了一批优秀的潜在学员，他们可以参加， 学员在这个项目中。该计划结合了两个世界级的导师，基础设施和资源 这些机构在临床和转化研究的一个至关重要的领域提供新的培训。

Abstract: This is a combined training grant from the University of North Carolina at Chapel Hill (UNC-CH) and Duke University (Duke UNC Immunotherapy Training Grant; DUNC-IMTG). The DUNC-IMTG will train postdoctoral fellows in translational and clinical research focusing on tumor immunotherapy and/or stem cell transplantation immunology. This is an area of rapid growth and interest with exciting new therapies being evaluated in the treatment of patients with multiple different forms of cancer. Despite this intense enthusiasm, these areas are vastly underrepresented in current training programs leading to a paucity of trained investigators to work in these rapidly expanding areas. The DUNC-IMTG supports the training of six trainees yearly at UNC-CH and Duke University. We have identified 21 senior mentors and 3 junior mentors with outstanding qualifications at UNC-CH and Duke University to instruct individuals supported by this training program. These investigators' interests include vaccine design and vector generation, adoptive cellular therapy, novel approaches to understand the function of checkpoint inhibitors, the role of immune cells in the tumor microenvironment and enhancing our understanding of the biology of immune cells in stem cell transplantation. We have an extremely novel mechanism for training with an emphasis on didactic coursework in statistical design, bioinformatics and proteomics, and seminar courses. Importantly, all trainees take these courses together, which allows access to trainees of each institution to world-class instructors from both institutions. All trainees will participate in Immunotherapy Working Groups, which are translational teams that assist in the development of novel immunotherapies, allowing all trainees to be involved in the development of biomarkers and clinical trials for the treatment of patients with cancer. Additionally, we have a robust and comprehensive approach to training underrepresented minorities. Strengths of the program include an extremely strong group of mentors with substantial experience training postdoctoral fellows, an outstanding leadership group with a long history of training translational and clinical investigators, the presence of world-class vaccine and transplant infrastructure allowing for the development and implementation of translational cutting-edge clinical trials and a strong track record of collaborative training grants with outstanding training success between Duke University and the University of North Carolina at Chapel Hill. Finally, we have identified an outstanding group of potential trainees who could participate as trainees in this program. This program combines the mentors, infrastructure and resources of two world-class institutions to provide novel training in a critically important area of clinical and translational research.